TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18387407

Group type: EXPERIMENTAL
Intervention: Corneas from donors <66.0 years
Number of subjects: 1090

Group type: COMPARATOR
Intervention: Corneas from donors ≥66.0 years
Number of subjects: 1090
Study: 11905457

Group type: EXPERIMENTAL
Intervention: Minimum therapy at presentation plus maximum therapy at local relapse
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 0
Study: 9654538

Group type: EXPERIMENTAL
Intervention: Enoxaparin (40 mg once daily, subcutaneously for not less than seven days)
Number of subjects: 307

Group type: COMPARATOR
Intervention: Compression stockings alone (placebo)
Number of subjects: 307
Study: 8077067

Group type: EXPERIMENTAL
Intervention: Metoprolol (early intervention trial)
Number of subjects: 1395
Study: 2572136

Group type: EXPERIMENTAL
Intervention: Vecuronium
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 189385

Group type: EXPERIMENTAL
Intervention: Terbutaline 0.25 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 10
Study: 28219437

Group type: EXPERIMENTAL
Intervention: Modified software with basic shortcut menu changes and evidence-based decision support based on USPSTF recommendations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual software (control group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modified software
Number of subjects: 0
Study: 26665978

Group type: EXPERIMENTAL
Intervention: EOB body cream
Number of subjects: 29
Study: 23546045

Group type: EXPERIMENTAL
Intervention: Itraconazole plus pemetrexed
Number of subjects: 23

Group type: COMPARATOR
Intervention: Pemetrexed alone (Control)
Number of subjects: 23
Study: 21807659

Group type: EXPERIMENTAL
Intervention: 40 g dark chocolate (>85% cocoa)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 40 g milk chocolate (≤35% cocoa)
Number of subjects: 40
Study: 19494810

Group type: EXPERIMENTAL
Intervention: Atorvastatin (20‐80 mg) before and after gastric bypass surgery
Number of subjects: 12
Study: 16441926

Group type: EXPERIMENTAL
Intervention: Beta-casein A1
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Beta-casein A2
Number of subjects: 15
Study: 14720197

Group type: EXPERIMENTAL
Intervention: Systemic capsaicin 0.25%
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 11387176

Group type: EXPERIMENTAL
Intervention: Probiotic milk with Lactobacillus GG
Number of subjects: 571

Group type: COMPARATOR
Intervention: Placebo milk without Lactobacillus GG
Number of subjects: 571
Study: 9408067

Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg per day
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 8270392

Group type: EXPERIMENTAL
Intervention: Single dose of cefuroxime (1.5 g i.v. on call to surgery)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Triple dose of cefuroxime (1.5 g i.v. on call to surgery followed by two additional doses of 750 mg i.v. each, 8 and 16 h after surgery)
Number of subjects: 100
Study: 29493058

Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 1195

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1195
Study: 27513476

Group type: EXPERIMENTAL
Intervention: Parental monitoring
Number of subjects: 257

Group type: COMPARATOR
Intervention: Parental distress
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Parental self-efficacy
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Authoritative parenting
Number of subjects: 257
Study: 25102877

Group type: EXPERIMENTAL
Intervention: Aspirin continuation (100mg/d)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Aspirin withdrawal 3 days pre-extraction
Number of subjects: 90

Group type: COMPARATOR
Intervention: Aspirin withdrawal 5 days pre-extraction
Number of subjects: 90
Study: 22018760

Group type: EXPERIMENTAL
Intervention: Dolutegravir (all doses combined)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Efavirenz
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Dolutegravir
Number of subjects: 205
Study: 19818562

Group type: EXPERIMENTAL
Intervention: Overcommitment (OC)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Depressive symptoms and work stress scores
Number of subjects: 200

Group type: COMPARATOR
Intervention: Dexamethasone/CRH test
Number of subjects: 200
Study: 18451744

Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing intrauterine system (LNG-IUS)
Number of subjects: 15
Study: 16442037

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo injection
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: StriVectin‐SD
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: DDF Wrinkle Relax
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: HydroDerm
Number of subjects: 77
Study: 14504114

Group type: EXPERIMENTAL
Intervention: 15 mL of an antacid suspension 4 times daily
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: 300 mg of colloidal bismuth subcitrate 4 times daily
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: 20 mg of famotidine twice daily
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo twice daily
Number of subjects: 82
Study: 10624993

Group type: EXPERIMENTAL
Intervention: IV ketamine 0.15 mg/kg after induction and normal saline at the end of surgery (PRE group)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: IV ketamine at the end of surgery (POST group)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Normal saline at the beginning and end of surgery (CONT group)
Number of subjects: 45
Study: 9098871

Group type: EXPERIMENTAL
Intervention: 0.12% betamethasone 17-valerate cream formulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chromameter assessment
Number of subjects: 0
Study: 8471654

Group type: EXPERIMENTAL
Intervention: Weighted feeding tubes
Number of subjects: 70

Group type: COMPARATOR
Intervention: Unweighted feeding tubes
Number of subjects: 70
Study: 3954175

Group type: EXPERIMENTAL
Intervention: Supraclavicular approach
Number of subjects: 500

Group type: COMPARATOR
Intervention: Infraclavicular approach
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Alternate approach after failure
Number of subjects: 500
Study: 31743365

Group type: EXPERIMENTAL
Intervention: 18-month web-based lifestyle modification intervention
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: ≥ 10% weight loss
Number of subjects: 216
Study: 29490538

Group type: EXPERIMENTAL
Intervention: Friendly VPs
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Disruptive VPs
Number of subjects: 46

Group type: COMPARATOR
Intervention: No patient story VPs
Number of subjects: 46
Study: 27372742

Group type: EXPERIMENTAL
Intervention: Caffeine (CAF, 6 mg kg(‐1))
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 15
Study: 24116922

Group type: EXPERIMENTAL
Intervention: Six-month intervention based on the Information-Motivation-Behavioral Skills (IMB) model
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 100
Study: 23327027

Group type: EXPERIMENTAL
Intervention: parecoxib 40 mg twice daily
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: metamizol 1 g three times daily
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: paracetamol 1 g three times daily
Number of subjects: 120

Group type: COMPARATOR
Intervention: normal saline (NaCl)
Number of subjects: 120
Study: 20558830

Group type: EXPERIMENTAL
Intervention: Intensive motor training program (n=30) with 3 sessions of physical therapy and a structured home exercise program for 4 weeks after discharge.
Number of subjects: 62

Group type: COMPARATOR
Intervention: Standard treatment group (n=32).
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Intensive motor training group (n=30).
Number of subjects: 62
Study: 17917468

Group type: EXPERIMENTAL
Intervention: Zen meditation (MED)
Number of subjects: 124

Group type: COMPARATOR
Intervention: no meditation (noMED)
Number of subjects: 124
Study: 16202862

Group type: EXPERIMENTAL
Intervention: High-flavonoid (HF) sweetie juice
Number of subjects: 12

Group type: COMPARATOR
Intervention: Low-flavonoid (LF) sweetie juice
Number of subjects: 12
Study: 12134377

Group type: EXPERIMENTAL
Intervention: Guided imagery
Number of subjects: 0

Group type: COMPARATOR
Intervention: No guided imagery (control group)
Number of subjects: 0
Study: 10430197

Group type: EXPERIMENTAL
Intervention: Indomethacin tocolysis (50 mg followed by 25 mg 6 hourly for 48 hours)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 34
Study: 7582391

Group type: EXPERIMENTAL
Intervention: Mebhydroline (Omeril) 100 mg t.i.d.
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 2221579

Group type: EXPERIMENTAL
Intervention: NO2 exposure (2-ppm peaks with 0.05 ppm background for 3 hours)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Continuous exposure to 1.5 ppm NO2 for 3 hours
Number of subjects: 24

Group type: COMPARATOR
Intervention: Air exposure (control)
Number of subjects: 24
Study: 532631

Group type: EXPERIMENTAL
Intervention: Ketogenic diet (low carbohydrate)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Hypocaloric diet
Number of subjects: 104
Study: 31182047

Group type: EXPERIMENTAL
Intervention: Structured skills training group (SSTG) based on dialectical behaviour therapy (DBT)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Active control group based on psychoeducation
Number of subjects: 184
Study: 27676603

Group type: EXPERIMENTAL
Intervention: Early fortification from the first feeding
Number of subjects: 80

Group type: COMPARATOR
Intervention: Late fortification
Number of subjects: 80
Study: 25704463

Group type: COMPARATOR
Intervention: Spherical off-the-shelf contact lenses (SL)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Custom toric contact lenses (TL)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Spectacles
Number of subjects: 23
Study: 23843099

Group type: EXPERIMENTAL
Intervention: Dabigatran 110 mg
Number of subjects: 4904

Group type: EXPERIMENTAL
Intervention: Dabigatran 150 mg
Number of subjects: 4904

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 4904
Study: 21606131

Group type: EXPERIMENTAL
Intervention: Metformin 2000 mg/day
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 19623081

Group type: EXPERIMENTAL
Intervention: Short-term psychotherapy (STP)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 100
Study: 17236959

Group type: EXPERIMENTAL
Intervention: Pd-103 and supplemental beam radiation
Number of subjects: 179
Study: 12817827

Group type: EXPERIMENTAL
Intervention: 15 g/day ethanol
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 30 g/day ethanol
Number of subjects: 14

Group type: COMPARATOR
Intervention: 0 g/day ethanol
Number of subjects: 14
Study: 10836489

Group type: EXPERIMENTAL
Intervention: 10 microg CCK‐4
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 9277075

Group type: EXPERIMENTAL
Intervention: Propofol (1.0‐2.5 mg/kg for induction, continuous infusion of 2‐12 mg/kg/h) with fentanyl (50 micrograms) and vecuronium (0.08 mg/kg for intubation)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Isoflurane with thiopental (3‐5 mg/kg for induction), succinylcholine (1‐2 mg/kg for intubation), and vecuronium as a muscle relaxant
Number of subjects: 60
Study: 8243428

Group type: EXPERIMENTAL
Intervention: High-fibre diet (experimental group)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Regular high-fibre diet (control group)
Number of subjects: 12
Study: 3533676

Group type: COMPARATOR
Intervention: 25 mg trazodone tds
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 50 mg trazodone tds
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 150 mg total daily trazodone
Number of subjects: 20
Study: 30954312

Group type: EXPERIMENTAL
Intervention: Decision aid intervention
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control questionnaire
Number of subjects: 140
Study: 27776458

Group type: EXPERIMENTAL
Intervention: Exercise program conducted three times a week for 6 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (recommended sports brassiere, refraining from caffeine and methylxanthine-containing foods, and simple analgesics)
Number of subjects: 20
Study: 26371358

Group type: EXPERIMENTAL
Intervention: Postpartum weight management program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 23287080

Group type: EXPERIMENTAL
Intervention: Levosimendan 0.1 μg/kg/min
Number of subjects: 60

Group type: COMPARATOR
Intervention: Dobutamine 5 μg/kg/min
Number of subjects: 60
Study: 22321495

Group type: EXPERIMENTAL
Intervention: Laser Peripheral Iridotomy (LPI)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Surgery Peripheral Iridectomy (SPI)
Number of subjects: 60
Study: 19841759

Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine solution
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 2.5% NaOCl
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 1% chlorhexidine gel
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 3% H2O2
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 100
Study: 16908915

Group type: EXPERIMENTAL
Intervention: Revised 4-variable MDRD Study equation
Number of subjects: 1628

Group type: COMPARATOR
Intervention: Original 6-variable MDRD Study equation
Number of subjects: 1628

Group type: COMPARATOR
Intervention: Cockcroft-Gault equation
Number of subjects: 1628
Study: 15680101

Group type: EXPERIMENTAL
Intervention: Uniportal endoscopic plantar fasciotomy
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (non-athletic patients)
Number of subjects: 16
Study: 11444444

Group type: EXPERIMENTAL
Intervention: Mepivacaine + clonidine (Mc)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Mepivacaine (Mo)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Ropivacaine + clonidine (Rc)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Ropivacaine (Ro)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Bupivacaine + clonidine (Bc)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Bupivacaine (Bo)
Number of subjects: 120
Study: 9753232

Group type: EXPERIMENTAL
Intervention: rebamipide 100 mg three times a day
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study: 7844059

Group type: EXPERIMENTAL
Intervention: Noncontingent presentation of food on a fixed-time schedule (e.g., FT 30 s)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Massed-reinforcement (food) control
Number of subjects: 4

Group type: COMPARATOR
Intervention: No-reinforcement control
Number of subjects: 4
Study: 2967830

Group type: EXPERIMENTAL
Intervention: Metrizamide
Number of subjects: 30

Group type: COMPARATOR
Intervention: Iohexol
Number of subjects: 30
Study: 29549829

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1 μg/kg bolus followed by 0.2-0.7 μg/kg/h infusion from induction of anesthesia to the end of surgery (group D1)
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1 μg/kg bolus (group D2)
Number of subjects: 354

Group type: COMPARATOR
Intervention: Saline (group S)
Number of subjects: 354
Study: 27052531

Group type: EXPERIMENTAL
Intervention: Folic Acid 400 μg/d
Number of subjects: 605

Group type: EXPERIMENTAL
Intervention: Folic Acid 800 μg/d
Number of subjects: 605

Group type: EXPERIMENTAL
Intervention: Creatine 3 g/d
Number of subjects: 605

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 605
Study: 25768068

Group type: EXPERIMENTAL
Intervention: Gait training on an instrumented treadmill with biofeedback, biweekly for 3 months
Number of subjects: 56

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 56
Study: 23111138

Group type: EXPERIMENTAL
Intervention: Diltiazem 360 mg/day
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Verapamil 240 mg/day
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Metoprolol 100 mg/day
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Carvedilol 25 mg/day
Number of subjects: 60

Group type: COMPARATOR
Intervention: Baseline (no treatment)
Number of subjects: 60
Study: 20935604

Group type: EXPERIMENTAL
Intervention: Glidescope®
Number of subjects: 44

Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 44
Study: 19394790

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 16436724

Group type: EXPERIMENTAL
Intervention: 400 mg b.i.d. (after 9 doses of 200 mg q.i.d.)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: 600 mg b.i.d. (after 9 doses of 400 mg q.i.d.)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: 800 mg q.d. (after 5 doses of 800 mg b.i.d.)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Overall mean exposure of 400 mg b.i.d.
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow transplant (BMT) recipients
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Treatment-related adverse events
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Adverse events leading to premature discontinuation
Number of subjects: 98
Study: 15545238

Group type: EXPERIMENTAL
Intervention: Ergonomic asymmetric fitted sock
Number of subjects: 16

Group type: COMPARATOR
Intervention: Standard running sock
Number of subjects: 16
Study: 11704101

Group type: EXPERIMENTAL
Intervention: 23-day EE/GSD
Number of subjects: 890

Group type: COMPARATOR
Intervention: 21-day EE/DSG
Number of subjects: 890

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 890
Study: 9422908

Group type: EXPERIMENTAL
Intervention: Intra-articular morphine 2 mg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Intra-articular clonidine 150 micrograms
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Combination of morphine and clonidine
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (isotonic saline solution)
Number of subjects: 90
Study: 8425242

Group type: EXPERIMENTAL
Intervention: Ranitidine 50 mg iv (RANIV group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ranitidine 50 mg im (RANIM group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo iv (PLAC group)
Number of subjects: 60
Study: 3277372

Group type: EXPERIMENTAL
Intervention: Cisplatin 50 mg/m2 intravenously every 21 days combined with razoxane 750 mg/m2 weekly
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Cisplatin 50 mg/m2 intravenously every 21 days combined with razoxane 1150 mg/m2 weekly
Number of subjects: 9
Study: 30321774

Group type: EXPERIMENTAL
Intervention: Kangaroo Mother Care (KMC)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Swaddling
Number of subjects: 61
Study: 28856580

Group type: EXPERIMENTAL
Intervention: Brivaracetam
Number of subjects: 1932

Group type: EXPERIMENTAL
Intervention: Levetiracetam
Number of subjects: 1932

Group type: COMPARATOR
Intervention: Placebo (Brivaracetam)
Number of subjects: 1932

Group type: COMPARATOR
Intervention: Placebo (Levetiracetam)
Number of subjects: 1932
Study: 26552352

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) effervescent tablets, daily dose based on weight, for 5 days
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 23299767

Group type: EXPERIMENTAL
Intervention: Caffeine supplementation (6 mg · kg(‐1) body weight, n = 17)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo (n = 16)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Caffeine supplementation
Number of subjects: 33
Study: 16642619

Group type: EXPERIMENTAL
Intervention: Scalp acupuncture plus general anesthesia
Number of subjects: 52

Group type: COMPARATOR
Intervention: General anesthesia only
Number of subjects: 52
Study: 12790816

Group type: EXPERIMENTAL
Intervention: Standard gum elastic bougie with nasendoscope
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard gum elastic bougie without nasendoscope
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Optimal curve bougie with nasendoscope
Number of subjects: 40

Group type: COMPARATOR
Intervention: Optimal curve bougie without nasendoscope
Number of subjects: 40
Study: 10549459

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 90

Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 90
Study: 7754482

Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2344697

Group type: EXPERIMENTAL
Intervention: D-propranolol (120 mg for 5 days)
Number of subjects: 40

Group type: COMPARATOR
Intervention: L-propranolol (120 mg for 5 days)
Number of subjects: 40
Study: 6102059

Group type: EXPERIMENTAL
Intervention: 5% saline
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: 20% saline
Number of subjects: 359
Study: 31432287

Group type: EXPERIMENTAL
Intervention: Prophylactic Bio‐A biosynthetic stripe (Gore) in a sub‐lay position
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard closure in double layer using PDS 0
Number of subjects: 100
Study: 29880779

Group type: EXPERIMENTAL
Intervention: Polar M400 smartwatches and Facebook group with PA tips
Number of subjects: 30

Group type: COMPARATOR
Intervention: Facebook group only (comparison group)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups (experimental and comparison)
Number of subjects: 30
Study: 28274276

Group type: EXPERIMENTAL
Intervention: L-citrulline for 24 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo for 24 weeks
Number of subjects: 30
Study: 26269653

Group type: EXPERIMENTAL
Intervention: Automated office blood pressure readings at systolic blood pressure of 135 to 144 mm Hg
Number of subjects: 3627

Group type: EXPERIMENTAL
Intervention: Automated office blood pressure readings at diastolic blood pressure of 80 to 89 mm Hg
Number of subjects: 3627

Group type: EXPERIMENTAL
Intervention: Automated office blood pressure readings with pulse pressure of 80 to 89 mm Hg
Number of subjects: 3627
Study: 24113042

Group type: EXPERIMENTAL
Intervention: Ambrisentan 2.5 mg or 5 mg once daily for 12 weeks
Number of subjects: 15
Study: 21958884

Group type: EXPERIMENTAL
Intervention: ABSORB BVS (Rev.1.1, Abbott Vascular)
Number of subjects: 56
Study: 18261199

Group type: EXPERIMENTAL
Intervention: Ethanol method
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: N(2)O method
Number of subjects: 86
Study: 16034469

Group type: EXPERIMENTAL
Intervention: Tadalafil 10 mg
Number of subjects: 1846

Group type: EXPERIMENTAL
Intervention: Tadalafil 20 mg
Number of subjects: 1846

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1846
Study: 12907410

Group type: EXPERIMENTAL
Intervention: Multimicronutrient-fortified complementary food
Number of subjects: 0